2013 USP Chapter <797> Compliance Survey & Current Practice Standards
|
|
- Bethanie Pitts
- 6 years ago
- Views:
Transcription
1 2013 USP Chapter <797> Compliance Survey & Current Practice Standards Kenneth S. Latta, BS, RPh Gates Healthcare Associates, Inc Hillsborough, NC
2 We Welcome Your Questions You can submit questions throughout the webinar, using the form on your screen. If you experience any technical issues during the webinar, please use the help button shown on your screen. Download a PDF handout of the presentation on the PharmacyAdvisor.com web page where you clicked to join today s webinar. 2 Disclosure The content of this presentation was created by the presenters and does not necessarily reflect the views of Baxter Healthcare Corporation. Our speaker has accepted an honorarium from Baxter for this presentation. 3
3 About Our Speaker Kenneth S. Latta, BS, RPh Manager Duke Compounding Facility 2000 to Pharmacy Compounding Accreditation Board Present Surveyor Standards Committee PCAB Medisca Network 2006 Present Co-Writer for Non-Sterile and Sterile Compounding Courses; Facilitator for Non-Sterile and Sterile Courses. Gates Healthcare Associates, Inc Senior Associate Present. Visante; Visante UK Senior Consultant 4 Objectives Identify the top 10 underperforming standards from the 2013 USP Chapter<797> Compliance Study. Discuss barriers that prevent compliance with these standards and ways to remove the barriers. Discuss the new recommendations possibly incorporated in the Revisions to USP <797> and the upcoming USP <800> Hazardous Drugs Handling in Healthcare Settings. Identify resources that can be employed to assist pharmacists in meeting these standards. 5
4 Compliance Improvement? 2011, 12, and 2012 National USP Chapter <797> Studies showed work practice related deficiencies Could be remedied with little financial impact Provided with many free resources Demonstrated little to no improvement in deficiencies 6 Challenges to USP <797> Implementation 7
5 Drivers of USP <797> Compliance 8 Survey Dynamics versus SBOP Dynamics Hospitals were 76% of study population (790/1045) Alternate site provider 11% Hospital pharmacies do not control budget Compounding pharmacies control own budget Hospital pharmacies do not completely set priorities Compounding pharmacies can set priorities Survey possibly selected for higher performing facilities 9
6 Facility Design (Secondary Engineering Controls) 10 Buffer only For buffer areas not physically separated from the ante-areas, the principle of displacement airflow shall be employed. 2 This concept utilizes a low pressure differential, high airflow principle. 2 Using displacement airflow typically requires an air velocity of 40 ft per minute or more from the buffer area across the line of demarcation into the antearea USP 36 NF 31 May to July 2013 USP <797> Pharmaceutical Compounding Sterile Preparations 11
7 Primary Engineering Control Not in ISO 7 12 hour BUD Segregated Compounding Area LAFW or BSC must be certified per CETA Gowned and garbed Sterile gloves Cleaning and Disinfection of area - Documented Monthly - ceiling, walls and storage shelving Daily - floors, counters, and easily cleanable work surfaces PEC per standard protocol Surface Sampling & Viable Air Sampling in PEC and Area with identification during certification 2. USP 36 NF 31 May to July 2013 USP <797> Pharmaceutical Compounding Sterile Preparations 12 Compounding Aseptic Isolator in non-iso 7 Must be certified to CETA and USP standards 2 Viable Environmental Sampling Surface and Air 3 Compounding Chamber Pass Through Chambers Non-ISO room in which it is located Colony Forming Units must be identified Tested under Operational or Dynamic Conditions USP highly pathogenic organisms Gram Negative Rods Coagulase Positive Staphylococcus Molds and Yeasts 2. USP 36 NF 31 May to July 2013 USP <797> Pharmaceutical Compounding Sterile Preparations 3. CETA Certification Application Guide USP <797> Viable Environmental Sampling & Gowning Evaluation 13
8 CAI Certification Section Field Test Mandatory Airflow Test 2.02 Chamber Pressure Test 2.03 Site Installation Assessment Tests 2.05 HEPA Filter Integrity TEST Mandatory Operational or Dynamic Conditions 2.08 Airflow Smoke Pattern Test 2.09 Preparation Ingress and Egress Test 2.10 Non-Viable Particulate Testing 2.06 Particulate Containment Integrity and Enclosure Leak Test (CACI HD Only) 4. CETA Compounding Isolator Testing Guide 14 Airflow Smoke Pattern Test should be performed on all unidirectional airflow clean-zones to verify unidirectional airflow. 5 should be done under dynamic operating conditions 5 actual compounding personnel should conduct the actual operations that will be carried out in the areas being tested. 5 should be witnessed by the compounding facility supervisors so they can determine optimal operating set-ups based on airflow patterns within the space CETA Certification Guide for Sterile Compounding Facilities 15
9 Facilities 16 Low Use Exemption If a CACI that meets the requirements of this chapter is used outside of a buffer area, the compounding area shall maintain a minimum negative pressure of 0.01-inch water column and have a minimum of 12 ACPHs. In facilities that prepare a low volume of hazardous drugs, the use of two tiers of containment (e.g., CSTD within a BSC or CACI that is located in a non-negative pressure room) is acceptable. Probably Going Away! 2. USP 36 NF 31 May to July 2013 USP <797> Pharmaceutical Compounding Sterile Preparations 17
10 Hazardous Compounding (NIOSH Listed) BSC or CACI shall be placed in an ISO Class 7 area physically separated (i.e., a different area from other preparation areas) optimally has not less than 0.01-inch water column negative pressure to adjacent positive pressure ISO Class 7 or better ante-areas, thus providing inward airflow to contain any airborne drug. 2. USP 36 NF 31 May to July 2013 USP <797> Pharmaceutical Compounding Sterile Preparations 18 Compounding Performed Outside of ISO 5 19
11 Environmental Monitoring in Hospitals 57% 53% 49% 38% 36% 30% 50% 50% 49% 20 Ongoing Gloved Fingertip Testing
12 Environmental Sampling Rationale Tool to measure effectiveness of: The Primary Engineering Controls The Secondary Engineering Controls Disinfecting Processes Work Practices Shows that the pharmacy is maintaining an adequate state of control. 1 In lieu of direct sterility testing of preparations; are important indicators that the final preparation may be sterile in the eyes of regulatory personnel. 22 Daily Air Pressure/Velocity Documentation 23
13 Rationale for Air Pressure/Velocity Marker for each facility to show ability to maintain a state of control Decreased particulates Decreased microbes Containment of NIOSH listed (Hazardous) Drugs USP <800> Hazardous Drugs Handling in Healthcare Settings Personal Protective Equipment for Health Care Workers Who Work with Hazardous Drugs o 2. USP 36 NF 31 May to July 2013 USP <797> Pharmaceutical Compounding Sterile Preparations 24 Filter Integrity Test Hospital Compliance 15.5% Overall Compliance 26.9% Mandatory test that indicates that the sterile filtration could possibly produce a sterile final preparation. Part of the overall picture that indicates that the facility design, cleaning and disinfecting processes, behaviors and components used could have resulted in a preparation that is sterile. Regulatory vision 2. USP 36 NF 31 May to July 2013 USP <797> Pharmaceutical Compounding Sterile Preparations 25
14 Line of Demarcation 42% of hospitals (n=70) are Non-Compliant 1 Costs no money Behavioral changes needed Effective way to reduce the introduction of particles and microbes into the compounding environment 26 Bacterial Endotoxin Testing 27
15 Bacterial Endotoxin Testing High Risk Compounding Non-sterile ingredients or components o Except those for inhalation and ophthalmic administration Required for > 25 items or Exposed longer than 12 2 C to 8 C or > 6hrs at > 8 C before they are sterilized Commercial Laboratory In House Gel clot Empiric methodology 2. USP 36 NF 31 May to July 2013 USP <797> Pharmaceutical Compounding Sterile Preparations 28 Sterility Testing Compliance Hospital compliance 25% 1 Overall compliance 31% 1 Required when Beyond-Use Date exceeds the storage times published in USP <797> High Risk CSPs prepared in batches >25 29
16 Sterility Testing Required if BUD Exceeds Risk Level Room Temperature Refrigerated Frozen Low Risk 48 hrs 14 days 45 days Medium Risk 30 hrs 9 days 45 days High Risk 24 hrs 3 days 45days 2. USP 36 NF 31 May to July 2013 USP <797> Pharmaceutical Compounding Sterile Preparations 30 USP <71> Compliant Membrane Filtration Membrane Filtration is used whenever the nature of the product permits. Method Suitability testing for each preparation Number of containers to be tested determined by volume of container, size of the batch and type of preparation Minimum of 1 ml from each container for each of the two test fluids 6. USP 36 NF 31 USP <71> Sterility Tests 31
17 Parenteral Containers per Batch Batch Size -2 ml or Greater Not more than 100 containers >100 to 500 containers 10 containers Minimum Number of Items to be Tested for Each Medium 10% or 4 Whichever is greater > 500 containers 2% or 20 containers, whichever is less Large Volume Parenterals Less than 2 ml Not more than 100 containers >100 to 500 containers 20 containers 2% or 10 containers, whichever is less 20% or 8 Whichever is greater > 500 containers 4% or 40 containers, whichever is less 6. USP 36 NF 31 USP <71> Sterility Tests 32 References 1. Douglass, K, et al. The 2013 USP Chapter <797> Compliance Survey Pharmacy Purchasing & Products. October 2013:S1 S USP 36 NF 31 May to July 2013 USP <797> Pharmaceutical Compounding Sterile Preparations. 3. CETA Certification Application Guide USP <797> Viable Environmental Sampling & Gowning Evaluation CAG Effective January 31, CETA Compounding Isolator Testing Guide CAG Revised December 8, CETA Certification Guide for Sterile Compounding Facilities CAG Revised January 31, USP 36 NF 31 USP <71> Sterility Tests. Baxter and Pharmacy Advisor are trademarks of Baxter International Inc. 33
18 We Welcome Your Questions You can submit questions throughout the webinar, using the form on your screen. If you experience any technical issues during the webinar, please use the help button shown on your screen. Download a PDF handout of the presentation on the PharmacyAdvisor.com web page where you clicked to join today s webinar. 34
2008 ASHP Summer Meeting Seattle, Washington Educational Session Abstracts
2008 ASHP Summer Meeting Seattle, Washington Educational Session Abstracts 116 USP Update 2008 and Personnel-Related Environmental Sampling Trissel, L.A. TriPharma Research, P.O. Box 265, Cashiers,
More informationUnidirectional Airflow Smoke Test Protocol
Unidirectional Airflow Smoke Test Protocol Persons signing as approvers shall have examined the Unidirectional Airflow Protocol. This approval shall signify that testing of operational parameters is adequate
More informationModel Standards for Pharmacy Compounding of Non-Sterile Preparations
Model Standards for Pharmacy Compounding of Non-Sterile Preparations Published with the Guidance Document For Pharmacy Compounding of Non-Sterile Preparations National Association of Pharmacy Regulatory
More informationUSP 800 and Hazardous Medications
USP 800 and Hazardous Medications Trung H. Nguyen, PharmD and Alesha Davis, CPhT Dayton VA Medical Center Trung.Nguyen610@va.gov Alesha.Davis@va.gov The speaker has no actual or potential conflict of interest
More informationSTERILITY TESTING OF PHARMACEUTICAL PRODUCTS
STERILITY TESTING OF PHARMACEUTICAL PRODUCTS Tim Sandle CONTENTS Introduction xiii 1 STERILITY 1 Introduction 1 Sterility 3 Microorganisms and Microbial Growth 5 Types of microorganisms 7 Sterilization
More informationSTANDARDS FOR PHARMACY COMPOUNDING OF NON-STERILE PREPARATIONS
STANDARDS FOR PHARMACY COMPOUNDING OF NON-STERILE PREPARATIONS ACKNOWLEDGEMENTS The standards in this document are based on the Model Standards for Pharmacy Compounding of Non-Sterile Preparations developed
More information6/7/2017 CHANGES IN PHARMA REGULATIONS HOW IT AFFECTS THE OR NURSE DISCLOSURE OBJECTIVES
CHANGES IN PHARMA REGULATIONS HOW IT AFFECTS THE OR NURSE John Karwoski, RPh, MBA DISCLOSURE I, John Karwoski, RPH, MBA have business relationships with the companies MOBIUS THERAPEUTICS, LLC, Cubex, and
More informationCompounding Medication Regulations
Association of Professors of Dermatology 2016 Annual Meeting Swissôtel, Chicago, IL Compounding Medication Regulations Christopher Bichakjian, MD Professor of Dermatology Comprehensive Cancer Center and
More informationLEAD SAFETY PROGRAM. Purpose. Scope. Responsibilities. Southern Heat Exchanger Services Safety Program
Page: Page 1 of 5 Purpose The purpose of this procedure is to identify the controls and actions necessary to prevent adverse health effects to employees from occupational exposure to lead, and to ensure
More informationCompounding Sterile Drugs: A Regulatory Update
Compounding Sterile Drugs: A Regulatory Update Fred Massoomi, Pharm.D., FASHP Senior Director Visante, Inc. March 21, 2017 Copyright Visante, Inc. 2017 www.visanteinc.com 1 Objectives Review incidents
More informationSurgiCube Clinical Tests
The use of the SurgiCube over critical zones and instruments to reduce air-borne contamination at intraocular ophthalmic surgeries Oogartsen Praktijk Delfland, Eye clinic Delft, The Netherlands August
More informationHow Do You Know If Your Sterilized Instruments Remain Sterile?
How Do You Know If Your Sterilized Instruments Remain Sterile? Disclosure Harry Shaffer is the first author of the sterility maintenance study covered in this presentation and has been compensated by Halyard
More informationDisclosure. Objectives. Objectives. Introduction. Introduction. Non-Sterile Compounding/Calculations
49th Annual Meeting Non-Sterile Compounding/ Sunil Jambhekar, B. Pharm., M.S., Ph.D Professor, Pharmaceutical Sciences LECOM Bradenton, School of Pharmacy Bradenton, FL 34211 Disclosure I do not have a
More informationIngredient Listing Qty. Unit NDC # Supplier g
8/16/2018; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Lidocaine, USP 0.400 g Stevia Powder 0.10 g Polyox TM WSR-301 Topical Adhesive Powder* 9.50 g *Formula # F 007 422 available
More informationEnvironmental Monitoring in the Cell Processing Laboratory What to do with the data?
Environmental Monitoring in the Cell Processing Laboratory What to do with the data? Shelly Heimfeld, Ph.D. Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance ISCT President Somatic Cell
More information247 CMR BOARD OF REGISTRATION IN PHARMACY
247 CMR 18.00: NON-STERILE COMPOUNDING Section 18.01: Authority and Purpose 18.02: Non-Sterile Compounding Process 18.03: Non-Sterile Compounding Facility 18.04: Non-Sterile Compounding Equipment 18.05:
More informationIngredient Listing Qty. Unit NDC # Supplier. q.s. to ml
12/20/2018; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier, USP 10 MU Sucrose, NF 23.00 g Propylene Glycol, USP 7.0 ml Medisca Oral Mix (Flavored Suspending Vehicle) 50.0 ml Medisca
More informationTalon Compounding Pharmacy 10/3/17
Talon Compounding Pharmacy 10/3/17 Office of Pharmaceutical Quality Operations, Division II 4040 N. Central Expressway, Suite 300 Dallas, Texas 75204 October 3, 2017 CMS Case # 522630 VIA UPS EXPRESS WARNING
More informationName Date: Pharmacy Education Resources National Intravenous Sterile Training Manual for Pharmacy Technicians TSHP Post-Test
Name Date: Pharmacy Education Resources National Intravenous Sterile Training Manual for Pharmacy Technicians TSHP Post-Test For each of the following questions circle the one most correct answer. (For
More informationTown and Country Compounding and Consultation Services, LLC 10/17/17
Town and Country Compounding and Consultation Services, LLC 10/17/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973)
More informationBiosafety Level 3 (BL3)
Biosafety Level 3 (BL3) NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (Appendix G-II-C) - April 2016 Biosafety Level 3 (BL3) Biosafety Level 3 is applicable to clinical,
More informationOpen Microphone Session on USP General Chapter <825> Radiopharmaceuticals Preparation, Compounding, Dispensing, and Repackaging
Open Microphone Session on USP General Chapter Radiopharmaceuticals Preparation, Compounding, Dispensing, and Repackaging October 10, 2018 11:00 am 1:00 pm ET General Chapter Open Microphone
More informationSterility Assurance and Risk Management: A CDER Microbiologist s Perspective
Sterility Assurance and Risk Management: A CDER Microbiologist s Perspective John W. Metcalfe, Ph.D. Senior Review Microbiologist FDA/CDER/OPQ/OPF/Division of Microbiology Assessment Center for Drug Evaluation
More informationHow Do You Know If a Sterilized Package Remains Sterile?
How Do You Know If a Sterilized Package Remains Sterile? 1 Acknowledgments Bioaerosol and Applied Microbiology Team Brian Heimbuch, MS Group Lead Del Harnish, MS Lead Technical Mike McDonald, MS Lead Engineer
More informationEnvironmental Monitoring How to Satisfy the Regulator. Presented by Tanja Varglien, July 2017
Environmental Monitoring How to Satisfy the Regulator Presented by Tanja Varglien, July 2017 Slide 1 PharmOut 2017 Using Glisser You will be able to tap the download link at the end of each presentation.
More informationPDA Points to Consider relating to EU GMP Annex 1 changes. Presented by Ashley Isbel 30 November, 2016
PDA Points to Consider relating to EU GMP Annex 1 changes Presented by Ashley Isbel 30 November, 2016 Lets get interactive! On your smart device, open a browser app and go to the link provided Click on
More informationName Date: Pharmacy Education Resources National Intravenous Training Manual for Pharmacists TSHP Post-Test
Name Date: Pharmacy Education Resources National Intravenous Training Manual for Pharmacists TSHP Post-Test For each of the following questions circle the one most correct answer. (For program credit make
More information"Understanding USP 71 Sterility Tests and Extending BUD"
"Understanding USP 71 Sterility Tests and Extending BUD" ERIC S. KASTANGO, M BA, RPH, FASHP CLINICAL IQ, LLC JULY 10, 2013 Disclaimer Although I am an Expert Consultant to the USP, I am speaking today
More informationFACEMASKS. Helping you face infection control. a comprehensive guide for safety and protection
E D U C A T I O N A L S E R I E S FACEMASKS Helping you face infection control a comprehensive guide for safety and protection Prevention is a lot easier when you re properly equipped with appropriate
More informationThe Therapeutic Goods Act (1989)
EDUCATION PRACTICE UPDATE Assigning expiry dates to compounded medications First published in the Australian Journal of Pharmacy, Vol. 99, No.1169, February 2018, pp.72-76. Reproduced and distributed by
More informationSterile Compounding. Jessica Tagerman, PharmD, Rph
Sterile Compounding Jessica Tagerman, PharmD, Rph What is Sterility? Sterility & Sterile Compounding Sterile = free from bacteria or other living microorganisms; totally clean Sterile compounding is the
More informationLegal Aspects in Intravenous Nutrient Therapy. Nayan Patel PharmD
Legal Aspects in Intravenous Nutrient Therapy Nayan Patel PharmD Objec;ves Understand state to state varia4on in laws to regulate office use Compounded IV Products. HR 3204; FDA jurisdic4on over compounding
More informationMedia Fill Test Kits. Manufactured by. Making USP <797> compliance easy!
Media Fill Test Kits Manufactured by Making USP compliance easy! Compliance was never so easy! Microbial Contamination Testing for CSPs Hardy Diagnostics offers all the products you need to easily
More informationUSP <797> Overview and Compliance Audit Results. Joseph W. Coyne RPh Director of Field Operations Clinical IQ, LLC
USP Overview and Compliance Audit Results Joseph W. Coyne RPh Director of Field Operations Clinical IQ, LLC Acknowledgements Many of the slides presented in this program come from the CriticalPoint
More informationA WHITE PAPER STERILITY TESTING ESSENTIAL THINGS YOU MUST KNOW
A WHITE PAPER STERILITY TESTING ESSENTIAL THINGS YOU MUST KNOW By Steven G. Richter, Ph.D 1. A WHITE PAPER STERILITY TESTING ESSENTIAL THINGS YOU MUST KNOW (includes combination products) Steven G. Richter
More informationAllergens Assessing risk and mapping your facility
Allergens Assessing risk and mapping your facility Evaluate and mitigate your allergen risks Allergen mapping is a part of allergen risk assessment and is an effective tool to identify and track allergens
More informationSingle Dose Vial / Repackaging FactFinder
Single Dose Vial / Repackaging FactFinder Committed to providing helpful information to International Spine Intervention Society members about key patient safety issues, the Society s Patient Safety Committee
More informationUni-directional Airflow Systems Working Height Velocity (WHV) Gordon Farquharson July 2017
Uni-directional Airflow Systems Working Height Velocity (WHV) Gordon Farquharson July 2017 Agenda: Uni-directional Airflow Systems Regulatory requirements & expectations. Measurement methods. Location
More informationEU Regulatory Update & GMP Deficiencies. Bryan J Wright July 2017
EU Regulatory Update & GMP Deficiencies Bryan J Wright July 2017 Slide 1 PharmOut 2017 Outline Update on changes in EU GMP Guide Summary of GMP changes to the Guide Important details of changes over the
More informationLaboratory Orientation and Safety
Laboratory Orientation and Safety Laboratory Safety Prevention of physical injuries and laboratory acquired infections with zoonotic disease agents Laboratory safety is every employee s responsibility!
More informationCleanroom vs. Isolator Concept Performance and cost comparison. Guy Turner, General Manager Bioquell Asia Pacific
Cleanroom vs. Isolator Concept Performance and cost comparison Guy Turner, General Manager Bioquell Asia Pacific guy.turner@bioquell.com Slide 1 PharmOut 2017 Requirements for Sterility Testing Environment
More informationTHE UNIVERSITY OF ALABAMA FUME HOOD MANAGEMENT PLAN
THE UNIVERSITY OF ALABAMA FUME HOOD MANAGEMENT PLAN ENVIRONMENTAL HEALTH AND SAFETY 410 CAMPUS DRIVE EAST BOX 870178 TUSCALOOSA, ALABAMA 35487 (205)348-5905 Table of Contents 1. Scope...3 2. Purpose.3
More information"LEAD EXPOSURE IN GENERAL INDUSTRY"
PRESENTER'S GUIDE "LEAD EXPOSURE IN GENERAL INDUSTRY" Training For THE OSHA LEAD STANDARD Quality Safety and Health Products, for Today... and Tomorrow OUTLINE OF MAJOR PROGRAM POINTS OUTLINE OF MAJOR
More informationRespiratory Protection for Exposures to the Swine Influenza A (H1N1) Virus: Health Care Workers
3M Canada Company P. O. Box / C.P. 5757 Compagnie 3M Canada London, Ontario N6A 4T1 3 April 29, 2009 Respiratory Protection for Exposures to the Swine Influenza A (H1N1) Virus: Health Care Workers Frequently
More informationCDC s Position Protect Patients Against Preventable Harm from Improper Use of Single-dose/Single-use Vials
Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases Division of Healthcare Quality Promotion Single-dose/Single-use Vial Position and Messages May 2,
More informationHieber's Pharmacy 12/5/17
Hieber's Pharmacy 12/5/17 Division of Pharmaceutical Quality Operations I 10 Waterview Blvd, 3rd FL Parsippany, NJ 07054 Telephone: (973) 331-4900 FAX: (973) 331-4969 CERTIFIED MAIL RETURN RECEIPT REQUESTED
More informationSAM HOUSTON STATE UNIVERSITY ENVIRONMENTAL HEALTH, SAFETY & RISK MANAGMENT
BLOODBORNE PATHOGENS PROGRAM I. PURPOSE The SHSU Bloodborne Pathogens program ensures SHSU compliance with Occupational Safety and Health (OSHA) Standard, 29 CFR 1910.1030, Blood Borne Pathogens. II. SCOPE
More informationLaboratory Ventilation Policy
-CH Laboratory Safety Manual Laboratory Ventilation Policy PURPOSE The University of North Carolina at Chapel Hill (University) is committed to providing students, faculty and staff with engineering controls
More informationWebinar. Risk Assessment Reusable Polyester and Single Use Tyvek IsoClean Cleanroom Garments Dupont
Webinar Risk Assessment Reusable Polyester and Single Use Tyvek IsoClean Cleanroom Garments Dupont 15 June 2018 GOP-Innovations your Partner for Practical Training and e-learning Milenko Pavičić Pharmaceutical
More informationDoc No: BLOOD Midland Engineering Co., Inc. Initial Issue Date 12/04/15 Safety Management System
Revision Preparation: Safety Mgr Authority: President Issuing Dept: Safety Page: Page 1 of 15 INTRODUCTION The Occupational Safety and Health Administration (OSHA) has a variety of regulations that all
More informationChapter 12. Preventing Infection. Elsevier items and derived items 2014, 2010 by Mosby, an imprint of Elsevier Inc. All rights reserved.
Chapter 12 Preventing Infection Infection Infection is a major safety and health hazard. The health team follows certain practices and procedures to protect patients, residents, visitors, and staff from
More informationOncology Pharmacy Practice Standards. Have CAPhO Standards of Practice Made a Difference? Oncology Pharmacy Practice Standards
Oncology Pharmacy Practice Standards Have CAPhO Standards of Practice Made a Difference? Larry Broadfield, BScPharm, MHSc, FCSHP Standards for safe handling of cytotoxic agents have been issued by several
More informationChapter 11 PREVENTING INFECTION. Elsevier items and derived items 2010 by Mosby, Inc. an affiliate of Elsevier Inc. All rights reserved
Chapter 11 PREVENTING INFECTION Infection is a major safety and health hazard. The health team follows certain practices and procedures to protect patients, residents, visitors, and staff from infection.
More informationChapter 13. Preventing Infection. Copyright 2019 by Elsevier, Inc. All rights reserved.
Chapter 13 Preventing Infection Copyright 2019 by Elsevier, Inc. All rights reserved. Lesson 13.1 Define the key terms and key abbreviations in this chapter. Identify what microbes need to live and grow.
More informationHistory Note: Authority G.S ; ; ; Eff. May 1, 1997; Amended Eff. January 1, 2015; March 1, 2013.
21 NCAC 46.1412 PHYSICAL REQUIREMENTS A health care facility pharmacy shall have sufficient floor space allocated to it to ensure that drugs are prepared in sanitary, well lighted, and enclosed places.
More informationSterile Product Preparation for Non-Pharmacy Personnel Dennis Sinclair, R.Ph..
Sterile Product Preparation for Non-Pharmacy Personnel Dennis Sinclair, R.Ph.. Objectives Describe the importance of accuracy and use of proper aseptic technique when preparing IV medications. Identify
More informationRespiratory Protection and Swine Influenza
PAGE 1 TechUpdate Respiratory Protection and Swine Influenza Frequently asked Questions The U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have recently issued
More informationCRYSTALLINE SILICA EMPLOYEE TRAINING
CRYSTALLINE SILICA EMPLOYEE TRAINING PROGRAM SYNOPSIS: Crystalline silica is a naturally occurring substance used in a wide variety of industries and construction operations such as the production of cement,
More informationQuestions from the Food Code Class
Questions from the Food Code Class 1. Question: I m interested in applying TPHC/TILT to the home delivered meals program. At what time would the start time begin for catered hot/cold food? Answer: Actually,
More information2016 Jurisprudence Update. (Phone) (Fax)
2016 Jurisprudence Update (Phone) 614-466-4143 (Fax) 614-752-4836 www.pharmacy.ohio.gov Goals and Objectives To explain recent law/rule changes which may apply to the pharmacy practice setting. To describe
More informationBloodborne Pathogens Exposure Control Plan
Bloodborne Pathogens Exposure Control Plan RIM of the World Unified School District 27315 North Bay Road Blue Jay, CA 92352 (909) 336-4100 July 2016 Safety and Risk Management Department RIM of the World
More informationDefining, achieving, and demonstrating effective performance of containment systems. Gordon Farquharson, July 2017
Defining, achieving, and demonstrating effective performance of containment systems Gordon Farquharson, July 2017 Slide 1 PharmOut 2017 Agenda Objectives and Principles. A hierarchy of containment techniques.
More informationPa. Immunization Education Program
Pa. Immunization Education Program 2016 Maintaining the Cold Chain The cold chain is a temperature-controlled environment used to maintain and distribute vaccine in optimal condition. Provider responsibility
More informationUNIT I EVOLUTION OF THE PHARMACY
Contents UNIT I EVOLUTION OF THE PHARMACY........................ 1 Chapter 1 Pharmacy History................................................. 3 Egyptian History 4 Greek Influence 4 British Apothecaries
More informationEnvironment CAUTION HEARING PROTECTION REQUIRED. Occupational Noise Exposure Requirements for Photographic Processing Facilities
Environment I N F O R M A T I O N F R O M K O D A K Occupational Noise Exposure Requirements for Photographic J-313(ENG) $10.00 Kodak s health, safety, and environmental CAUTION HEARING PROTECTION REQUIRED
More informationRespirators: One Way of Protecting Workers Against Pandemic Flu
Factsheet #3 What Workers Need to Know About Pandemic Flu Respirators: One Way of Protecting Workers Against Pandemic Flu When a person infected with pandemic flu coughs, sneezes, or talks, very small
More informationEnergy-Efficient Biological Safety Cabinet Reduces Energy Costs While Ensuring Safety
Energy-Efficient Biological Safety Cabinet Reduces Energy Costs While Ensuring Safety Robert Lloyd David C. Eagleson Dennis Eagleson ABSTRACT As the primary containment devices within laboratories, biological
More information3/2/2018. Christopher M. Dembny R.Ph. Dembny Pharmacy Consultants LLC Learning Objectives. Rule Compliance is Stimulating
Christopher M. Dembny R.Ph. Dembny Pharmacy Consultants LLC cdembny2@gmail.com Learning Objectives Rule Compliance is Stimulating 1 Biography 2 3 This is a broad and confusing issue for many centers. Information
More informationISO 13485:2016 MEDICAL DEVICES QMS TRANSITION GUIDE
ISO 13485:2016 MEDICAL DEVICES QMS TRANSITION GUIDE ISO 13485, OVERVIEW ISO 13485 sets regulatory requirements or, when specified, customer requirements for a management system for medical devices or services.
More informationRisk Based Environmental Monitoring
Risk Based Environmental Monitoring Presented by Tanja Varglien, August 2018 Slide 1 PharmOut 2018 Agenda Module 1 What is Environmental Monitoring Module 2 Regulatory requirements Module 3 Risk-based
More informationMohawk Valley Health System Infection Prevention. Annual Mandatory Education
Mohawk Valley Health System Infection Prevention Annual Mandatory Education Infection Prevention is Everyone s Responsibility Here are some steps that you can take to help prevent healthcare acquired infections
More informationPolicy Guide Injectable Hydromorphone Maintenance Treatment (2018)
Professional Practice Policy #67 Policy Guide Injectable Hydromorphone Maintenance Treatment (2018) P2 Injectable Hydromorphone Maintenance Treatment Policy Guide All pharmacy managers, staff pharmacists,
More informationAMENDATORY SECTION (Amending WSR , filed 10/10/95, effective 11/10/95)
AMENDATORY SECTION (Amending WSR 95-21-041, filed 10/10/95, effective 11/10/95) WAC 246-817-601 Purpose. The purpose of WAC 246-817-601 through ((246-817-630)) 246-817-660 is to establish requirements
More informationGeneral concepts in the Ph. Eur.: theory and rationale
General concepts in the Ph. Eur.: theory and rationale Cathie VIELLE Head of European Pharmacopoeia Department, EDQM / CoE 1 The structure of the Ph. Eur. General monographs Dosage form monographs General
More informationCity of Montpelier, Vermont The Smallest Capital City in the United States BLOODBORNE PATHOGENS EXPOSURE CONTROL PLAN AND PROCEDURES
City of Montpelier, Vermont The Smallest Capital City in the United States BLOODBORNE PATHOGENS EXPOSURE CONTROL PLAN AND PROCEDURES Last Updated June 19, 2003 1 Bloodborne Pathogens Exposure Control Plan
More informationAppendix C. RECOMMENDATIONS FOR INFECTION CONTROL IN THE HEALTHCARE SETTING
Appendix C. RECOMMENDATIONS FOR INFECTION CONTROL IN THE HEALTHCARE SETTING Infection Control Principles for Preventing the Spread of Influenza The following infection control principles apply in any setting
More informationCDC Health Advisory 04/29/2009
H1N1 (Swine Flu) is a sub-type of Influenza A. Wexford Labs disinfectants are effective against Influenza A. Current CDC Recommendations for Environmental Control in the Healthcare Setting: CDC Health
More informationIngredient Listing Qty. Unit NDC # Supplier. Sterile Preparation
4/23/2015; Page 1 SUGGESTED FORMULATION Ingredient Listing Qty. Unit NDC # Supplier Nifedipine, USP 0.975 g Silica Gel (Micronized) 0.75 g Medisca SPG Supposi-Base 189.06 g SPECIAL PREPARATORY CONSIDERATIONS
More informationAnesthetic Gases in Veterinary Clinics
Anesthetic Gases in Veterinary Clinics As an owner or employee of a veterinary clinic, we have all had questions regarding the safety of anesthetic gases. (1) Are these agents toxic? (2) Are there consequences
More informationEffective Airflow Visualization Studies. Gordon Farquharson, July 2017
Effective Airflow Visualization Studies Gordon Farquharson, July 2017 Slide 1 PharmOut 2017 Agenda Regulatory imperative Role of CFD Air velocity measurements Airflow visualisation to prove effectiveness
More informationPROCEDURE TITLE: BLOOD BORNE PATHOGENS EXPOSURE CONTROL PLAN PROCEDURE NO.: 5.21:1
PROCEDURE TITLE: BLOOD BORNE PATHOGENS EXPOSURE CONTROL PLAN PROCEDURE NO.: 5.21:1 RELATED POLICY: 5.21REV PAGE NO.: 1 OF 9 RESPONSIBLE ADMINISTRATOR(S): VPF&A/EHS EFECTIVE DATE: 07/11/14 NEXT REVIEW DATE:
More informationQuality. Guaranteeing High Quality. Outsourced Pharmacy Services. Disclosure 3/18/2013
Disclosure Outsourced Pharmacy Services By: Eddie Bostic, RPh For: South Carolina Society of Health System Pharmacist Annual Meeting, March 24 th 2013 Charleston, SC The views and opinions expressed in
More informationQuality, Safety and Sourcing in Unlicensed Medicines
Quality, Safety and Sourcing in Unlicensed Medicines with Andrew Trouton Managing Director, UL Medicines Agenda Welcome What is an unlicensed medicine? When should you consider using an unlicensed medicine?
More informationAllergy Vial Preparations and USP 797. Donald W Aaronson MD JD MPH
Allergy Vial Preparations and USP 797 Donald W Aaronson MD JD MPH Compounded Sterile Preparations (CSP) = USP 797 History Compliance with USP 797 has always been in the law with respect to physicians offices
More informationTIP NO AEROSOLIZED DRUGS TECHNICAL INFORMATION PAPER NO PURPOSE.
AEROSOLIZED DRUGS TECHNICAL INFORMATION PAPER NO. 56-088-0618 PURPOSE. Healthcare workers risk exposure to exhaled aerosolized drugs along with infectious airborne pathogens during administration and routine
More informationLarry! 28/06/2016. House Keeping. Welcome! From the GoToWebinar page:
A Review of Sterilization Methods and Recommended Practices for Healthcare Facilities PART I June 30, 2016 Larry Talapa Welcome! Topic: A Review of Sterilization Methods and Recommended Practices for Healthcare
More informationBiosafety in the Animal Setting. Tina Bogac Institutional Biosafety Officer
Biosafety in the Animal Setting Tina Bogac Institutional Biosafety Officer May 27, 2009 Biohazards and Biosafety Risk groups/risk assessment Biosafety/animal biosafety levels Essential work practices Biosafety
More informationSTERI-PEROX. Technical Data File. 3% & 6% Hydrogen Peroxide Solution VL Rev. 20 January 2012
STERI-PEROX 3% & 6% Hydrogen Peroxide Solution VL-901-98 Rev. 20 January 2012 Technical Data File, 15 Lee Boulevard, Malvern, PA 19355 USA T: 610-644-8335 F: 610-644-8336 www.sterile.com 1 of 12 STERI-PEROX
More informationAseptic Technique and Sterile Compounding
Aseptic Technique and Sterile Compounding Chapter 12 1 Introduction Hospital technician crucial responsibility: Proper preparation of parenteral products Contamination must be reduced when preparing parenterals
More informationChapter 9 TOBACCO AND SYNTHETIC NICOTINE CONTROL
1-9-1: PURPOSE: 1-9-2: SCOPE: 1-9-3: DEFINITIONS: Chapter 9 TOBACCO AND SYNTHETIC NICOTINE CONTROL 1-9-4: AUTHORITY AND APPLICABLE LAWS: 1-9-5: TOBACCO RETAIL PERMIT: 1-9-6: TOBACCO RETAILER; ELECTRONIC
More informationIARC - International Agency for Research on Cancer - Classifies carcinogens in the following manner:
ESHD 5008, Section 8, Chapter 2 Carcinogens, Mutagens, and Teratogens Rev. 3 Page 1 of 10 Approved 10/21/98 CHAPTER 2 CARCINOGENS, MUTAGENS, AND TERATOGENS 2.1 INTRODUCTION The purpose of this chapter
More informationHepatitis C 02/20/2017. It does happen! Outbreaks
Hepatitis C STRATEGIES TO PREVENT SPREAD OF HEPATITIS C IN THE WORKPLACE NORMA GOMEZ, MBA, MSN, RN, CNE It does happen! "A recent publication describes a dialysis facility where an outbreak of HCV continued
More informationUNDERSTANDING THE CONTENT OUTLINE/CLASSIFICATION SYSTEM
BOARD OF PHARMACY SPECIALTIES ONCOLOGY PHARMACY SPECIALIST CERTIFICATION CONTENT OUTLINE/CLASSIFICATION SYSTEM FINALIZED SEPTEMBER 2016/FOR USE ON FALL 2017 EXAMINATION AND FORWARD UNDERSTANDING THE CONTENT
More informationInfection Preventionist Series
Infection Preventionist Series Webinar 5: Frequent Citations: What Are We Missing? Diane Dohm MT, IP, CIC, CPHQ MetaStar April 3, 2018 Infection Preventionist Series Surveillance What data should we collect?
More informationRespiratory Protection for Exposures to the Influenza A (H1N1) Virus. Frequently Asked Questions (FAQs)
3M Occupational Health and 3M Center Environmental Safety Division St. Paul, MN 55144-1000 651 733 1110 Respiratory Protection for Exposures to the Influenza A (H1N1) Virus Frequently Asked Questions (FAQs)
More informationAbu Dhabi Occupational Safety and Health System Framework (OSHAD-SF) Code of Practice
Abu Dhabi Occupational Safety and Health System Framework (OSHAD-SF) Code of Practice CoP 1.2 Lead Exposure Management Version 3.1 July 2017 Table of Contents 1. Introduction... 3 2. Training and Competency...
More informationFacility and Management
Training Course of Microbial Resources Information Management and Utilization for Developing Countries BSL-3 Laboratory Facility and Management Dr. Yiping Zhu Sep. 14 2016 Pathogens and BSL-3 laboratory
More informationThe USP and Compounding Nonsterile Medications
November 21, 2015 Association of Portuguese Hospital Pharmacists The USP and Compounding Nonsterile Medications Lisa D. Ashworth, BS Pharm, RPh, FACA Compounding Specialist and Clinical Pharmacist, Children
More informationChapter 11. Preparing and Handling Sterile Products and Hazardous Drugs. Paradigm Publishing, Inc. 1
Chapter 11 Preparing and Handling Sterile Products and Hazardous Drugs Paradigm Publishing, Inc. 1 Preparing Intravenous Products IV route of administration can be used to Reach therapeutic drug serum
More information"GUARDING AGAINST TUBERCULOSIS IN HEALTHCARE FACILITIES"
MAJOR PROGRAM POINTS "GUARDING AGAINST TUBERCULOSIS IN HEALTHCARE FACILITIES" Training For THE CDC "TUBERCULOSIS PREVENTION GUIDELINES" "Quality Safety and Health Products, for Today...and Tomorrow" Outline
More information